$LUNG

Lehman David Aaron sold $5K of LUNG

Lehman David Aaron (GENERAL COUNSEL) sold 3,539 shares of Pulmonx Corp (LUNG) at $1.54 on 2026-06-01.

Original reporting
SEC EDGAR · Lehman David Aaron
Published Jun 3, 2026, 8:17 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 3, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LUNG
Bearish
medium confidence
Mentioned
$LUNG
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LUNGBearishLow
01

Why it matters

The disclosure provides incremental sentiment information but does not include new business, clinical, or financial results.

02

Market read

Traders may note the insider sale for sentiment/positioning, but it is unlikely to drive a major repricing absent other catalysts.

03

What to watch

No 10b5-1 plan is cited; however, absence of a plan detail alone is not sufficient to infer intent without additional filings or context.

Relevance 6/10Novelty 6/10Timing: Filed 2026-06-03; sale executed 2026-06-01.

Background

This is an SEC Form 4 insider transaction disclosure (officer/general counsel) for Pulmonx Corp.

Company-level read

Ticker impact

$LUNGBearishMedium confidence
Context

Pulmonx insider (general counsel) filed an open-market sale of 3,539 shares at $1.54 on 2026-06-01.

Expected impact

Likely small, short-lived negative bias; limited follow-through unless accompanied by other news.

Evidence & confidence

The filing is a routine insider transaction with no 10b5-1 plan stated and no accompanying operational/financial disclosure, so impact is typically muted.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide signal.

None indicated.

None indicated.

Counterpoint

Insider sales can be routine for diversification/tax and do not necessarily reflect negative fundamentals.

Key entities

  • Pulmonx Corp

    Subject of the Form 4 insider sale; shares sold at $1.54 on 2026-06-01.

  • Lehman David Aaron

    General counsel who sold 3,539 shares (open-market sale).

Related articles

$GCTKMed

Top Biotech Gainers: GCTK On The Move, BHC, CORT Boost FY'26 Outlook, NEOG On Watch

Today's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others. Read on… GCTK's LT-100 Program Moves Forward Glucotrack Inc.

$LUNGMed

Pulmonx Stock Rises On Narrowed Q2 Losses, Margin Gains

Pulmonx (LUNG) reported Q2 2026 results for the quarter ended June 30, 2026. Revenue fell 5% to $22.8M, while gross profit rose to $17.7M and gross margin increased to 78%. Net loss narrowed to $10.1M ($0.24/share). The company reaffirmed FY2026 revenue guidance of $90M-$92M and gross margin around 76%.

$LUNGMed

Pulmonx Corp (LUNG): Results of Operations and Financial Condition

Pulmonx Corp (LUNG) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 lung2q26earningsrelease072.htm EX-99.1 Document Exhibit 99.1 Pulmonx Reports Second Quarter 2026 Financial Results Redwood City, CA - July 29, 2026 – Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lu